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Edited by Jesus AvilaAbstract Aggregated b-amyloid (Ab) peptides are neurotoxic
and cause neuronal death both in vitro and in vivo. Although
the formation of a b-sheet structure is usual required to form
aggregates, the relationship between neurotoxicity and the Ab
sequence remains unclear. To explore the correlation between
Ab sequence, secondary structure, aggregative ability, and
neurotoxicity, we utilized both full-length and fragment-trun-
cated Ab peptides. Using a combination of spectroscopic and cel-
lular techniques, we demonstrated that neurotoxicity and
aggregative ability are correlated while the relationship between
these characteristics and secondary structure is not signiﬁcant.
The hydrophobic C-terminus, particularly the amino acids of
17–21, 25–35, and 41–42, is the main region responsible for
neurotoxicity and aggregation. Deleting residues 17–21, 25–35
or 41–42 signiﬁcantly reduced the toxicity. On the other hand,
truncation of the peptides at either residues 22–24 or residues
36–40 had little eﬀect on toxicity and aggregative ability. While
the N-terminal residues 1–16 may not play a major role in neuro-
toxicity and aggregation, a lack of N-terminal fragment Ab pep-
tide, (e.g. Ab17–35), does not display the neurotoxicity of either
full-length or 17–21, 25–35 truncated Ab peptides.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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structure1. Introduction
Alzheimers’ disease (AD) is a neurodegenerative disorder
and the leading cause of senile dementia [1]. The major patho-
logical hallmarks in the brains of AD patients are amyloid
senile plaques (SPs). SPs, which are extracellular aggregates
of insoluble protein ﬁbrils, are comprised of two small, hydro-
phobic peptide-amyloid b(Ab) spanning residues 1–40 (Ab40)
and 1–42 (Ab42). The amyloid cascade hypothesis predicts
that this b-amyloid plaque development in the brain has an
early and essential role in the neuronal degeneration that leads
to dementia [1]. Ab is derived from a ubiquitous type I trans-
membrane protein, – amyloid precursor protein (APP) [2]. The
generation of Ab from APP is mainly a two-step cleavage pro-*Corresponding author. Fax: +886 3 8571917.
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0014-5793/$32.00  2007 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2007.02.026cess. The initial proteolysis by the aspartyl proteinase, – b-
secretase results in a residual C-terminal fragment containing
the transmembrane and cytoplasmic domains of APP [3].
The second step involves an intramembranous cleavage by a
c-secretase, an aspartic protease, to release Ab [4]. The ‘‘amy-
loid cascade’’ hypothesis has deﬁned the amyloid deposits of
Ab as a toxic agent [4,5]. Recent debate has focused on
whether ﬁbrils (amyloid) or soluble oligomers of Ab are the ac-
tive species that contribute to neurodegeneration and dementia
[6].
In addition to Ab40 and Ab42, SPs in Alzheimer’s patients
also contain other truncated forms of Ab, including Ab25–
35, Ab17–40, and Ab17–42 [7,8]. In vitro, a longer carboxyl
terminus has been shown to favor aggregation [9]. The
Ab25–35 fragment has frequently been used to replace full-
length Ab for aggregation or toxicity studies [10,11]. Recently,
Liu et al. investigated the aggregation of Ab using diﬀerent Ab
fragments, including Ab1–11, Ab1–16, Ab1–28, Ab10–20,
Ab12–28, Ab17–28, Ab17–40, Ab20–29 and Ab25–35 [12].
They concluded that residues 17–21 and 30–35 are important
regions for aggregation. To date, however, no systematic study
has been performed to investigate the correlation between
neurotoxicity and the length of Ab. Therefore, in the present
study, we synthesized diﬀerent fragment-truncated Ab peptides
to study the neurotoxicity, aggregation and secondary struc-
ture, and to determine the relationships between these charac-
teristics.2. Materials and methods
2.1. Synthesis of Ab peptide
The synthesis of full-length Ab40 and Ab42 as well as the other trun-
cated Ab peptides (listed in Table 1) was performed in an ABI 433A
solid-phase peptide synthesizer following the standard protocol. Cleav-
age and deprotection of the synthesized peptide were performed by
treatment with a mixture of triﬂuoroacetic acid /distilled water/phe-
nol/thioanisole/ethanedithiol. The peptide was then extracted with
1:1 (v:v) ether:H2O containing 0.1% 2-mercaptoethanol. The synthe-
sized Ab peptides were puriﬁed on a reverse-phase C-18 HPLC with
a linear gradient from 0% to 100% acetonitrile. The molecular weights
of Ab peptides were veriﬁed by MALDI-TOF mass spectroscopy.2.2. Cell culture
The rat pheochromocytoma cell line (PC12) was obtained from the
American Type Culture Collection (ATCC). The PC12 pheochromocy-
toma was cultured in Ham’s F12K medium with 15% (v/v) horseblished by Elsevier B.V. All rights reserved.
Table 1
Sequences of synthesized Ab peptides in this study
Symbol Sequence
-------05--------10-------15-------20-------25-------30-----35--------40--
Aβ42 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 
Aβ40 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV-- 
Aβ42(–36–40) DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLM----------IA 
Aβ40(–36–40) DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLM------------- 
Aβ42(–25–35) DAEFRHDSGYEVHHQKLVFFAEDV---------------------VGGVVIA 
Aβ40(–25–35) DAEFRHDSGYEVHHQKLVFFAEDV---------------------VGGVV--- 
Aβ42(–22–24) DAEFRHDSGYEVHHQKLVFFA------GSNKGAIIGLMVGGVVIA
Aβ40(–22–24) DAEFRHDSGYEVHHQKLVFFA------GSNKGAIIGLMVGGVV--- 
Aβ42(–17–21) DAEFRHDSGYEVHHQK---------EDVGSNKGAIIGLMVGGVVIA 
Aβ40(–17–21) DAEFRHDSGYEVHHQK---------EDVGSNKGAIIGLMVGGVV--- 
Aβ42(–17–35) DAEFRHDSGYEVHHQK-------------------------------------VGGVVIA 
Aβ40(–17–35) DAEFRHDSGYEVHHQK--------------------------------------VGGVV-- 
Aβ17–35 ---------------------------------LVFFAEDVGSNKGAIIGLM--------------
Aβ1–16 DAEFRHDSGYEVHHQK---------------------------------------------------
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Fig. 1. Comparison of neurotoxicity of full-length and truncated Ab
peptides. Ab peptides at a ﬁnal concentration of 50 lM were
coincubated with PC12 cells for 48 h. The percentage of cell viability
was measured using the WST-1 assay. The wells containing PC 12 cells
without Ab peptides were used as negative control.
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37 C in a humidiﬁed atmosphere containing 5% CO2. The cell suspen-
sion was obtained by passing the culture through a 22-gauge needle
three times. Cells were subcultured every 4 or 5 days with a split ratio
of 1:3 to 2:3. PC 12 cells were diﬀerentiated with 50 ng/ml NGF in
Ham’s F12K in the absence of serum.
2.3. Cell viability assay
The cell viability was measured using the WST-1 assay, in which the
tetrazolium salt (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazo-
lio]-1,3-benzene disulfonate) is reduced to a colored formazan by active
cells [13]. Diﬀerent Ab peptides were prepared as a 1 mM stock solu-
tion in DMSO. Fresh prepared stock solution was then dried under
N2 gas, and resupended in PBS buﬀer, pH 7.0, to a ﬁnal peptide con-
centration of 500 lM. The resulting solution was incubated at 25 C
for 24 h. This incubated peptide solution was further diluted to the de-
signed peptide concentrations for viability assay and IC50 estimation.
In a 96-well microtiter plate, 5 · 105 cells were incubated in the absence
or presence of Ab peptides in a total volume of 100 ll per well for 48 h
at 37 C in a humidiﬁed atmosphere containing 5% CO2 before the via-
bility assay. The WST-1 solution (10 ll) was added to each well, and
the wells were incubated for another 0.5–4 h at room temperature.
The absorbance was measured at a wavelength of 450 nm using a
microtiter plate reader. The IC50 values were estimated by performing
a series of concentration of Ab peptides ranging from 5 lM to
1500 lM.
2.4. Peptide aggregation assay
Thioﬂavin-T (ThT) was used to monitor the aggregation state of Ab
peptides [14]. Peptides were prepared as a 1 mM stock solution in
DMSO, dried under N2 gas, and resuspended in 25 mM phosphate
buﬀer, pH 7.4 to a ﬁnal peptide concentration of 50 lM. The resulting
solutions were dispended into 1.5 ml vials, and stored at 80 C until
used. In order to accelerate the aggregation process, all experiments
were carried out at a ﬁnal peptide concentration of 15 lM with
3 lM ThT and 0.01% NaN3 at 37 C. The ﬂuorescence measurements
were performed on the PE LS50B ﬂuorimeter equipped with a 96-well
microplate ﬂuorescence reader at 25.0 ± 0.2 C. The excitation and
emission wavelengths were 440 nm and 485 nm, respectively.
2.5. Circular dichroism spectroscopy and secondary structure analyses
For CD measurements, the peptide stock solutions, as prepared, and
stored as in section of aggregation assay, were further diluted with
25 mM phosphate buﬀer, pH 7.4, containing 2% triﬂuoroethanol, to
a ﬁnal Ab peptide concentration of 10 lM, and incubated at 25 C
for 48 h before CD measurement. CD spectra were recorded using a
Jasco 715 spectropolarimeter equipped with a thermal circulator acces-
sory. All measurements were performed in quartz cells with a path-
length of 0.1 cm. Data were collected at wavelengths from 190 to
260 nm in 0.2 nm increments. Every CD spectrum is reported as theaverage from at least three individual samples. The reported CD spec-
tra were corrected for baseline using the phosphate buﬀer, pH 7.4. All
measurements were carried out at 25.0 ± 0.2 C. Secondary structure
analysis was performed in an online web sever: Dicroweb [15,16].
CDSSTR program [17] was used to estimate the related secondary
structure. A normalized root mean standard deviation (NRMSD)
[18] was applied to indicate the quality of ﬁt for each spectrum, such
that:
NRMSD ¼ ½ðhobsðkÞ  hcalðkÞÞ2=ðhobsðkÞÞ21=2
where hobs(k) and hcal(k) are the observed and calculated ellipticities,
respectively. A low value for NRMSD suggests a good correlation be-
tween the calculated values and the experimental data.3. Results
3.1. Neurotoxicity induced by Ab peptides
For cell viability assay and IC50 estimation, various concen-
trations of diﬀerent Ab peptides ranging from 5 lM to
1500 lM were used. Fig. 1 shows the comparative cell viability
for 50 lM of Ab40, Ab42, and the other fragment-truncated
peptides.
The related IC50 values are summarized in Table 2. The
neurotoxicity induced by the Ab42, Ab40 and Ab42(–36–40)
and Ab40(–36–40) peptides was much stronger than for the
other truncated Ab peptides. The IC50 values for the Ab42,
Ab40, Ab42(–36–40), and Ab40(–36–40) peptides were
approximately 39 lM, 75 lM, 53 lM and 100 lM, respec-
tively. The IC50 values for all of these peptides were less than
100 lM, indicating that the amino acid sequence of Ab be-
tween 36–40 might not be the main region responsible for
the neurotoxicity. Moreover, the IC50 values of the Ab40
and Ab40(–36–40) peptides are about 2-fold higher than those
induced by the Ab42 and Ab42(–36–40) peptides. This result
suggests that amino acids I41 and V42 play an important role
in neurotoxicity.
Since residues 17–35 of Ab contains highly hydrophobic ami-
no acids, and this region has been proposed to be the main
region for aggregation [9], we synthesized the 17–35 truncated
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Fig. 2. Aggregation of full-length and truncated Ab peptides: Ab40
(–n–), Ab40(–25–35) (––), Ab40(–17–21) (–m–), Ab40(–17–35)
(–.–), Ab42 (–r–), Ab42(–17–35) (–b–), Ab42(–36–40) (–c–), and
Ab40(–22–24) ( ). The aggregation study was performed with
15 lM of Ab peptides, 3 lM Th-T and 0.01% NaN3 at 37 C.
Table 2
Calculated IC50 values and secondary structure of Ab peptides from
PC12 cell viability and CD spectra
Sequence IC50 a-Helix b-Sheet Random coil
Ab40 75 ± 14 5 40 55
Ab40(–17–21) 327 ± 2 5 30 65
Ab40(–22–24) 128 ± 8 5 28 66
Ab40(–25–35) 272 ± 6 5 35 60
Ab40(–36–40) 100 ± 10 6 32 62
Ab40(–17–35) 1300 ± 30 49 26 25
Ab42 38 ± 8 3 42 55
Ab42(–17–21) 208 ± 6 4 33 63
Ab42(–22–24) 110 ± 6 3 29 68
Ab42(–25–35) 150 ± 7 5 37 58
Ab42(–36–40) 52 ± 13 5 33 61
Ab40(–17–35) 703 ± 26 53 21 26
Ab17–35 300 ± 25 6 45 49
Ab1–16 NA 57 14 29
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shown in Table 2, it can be found that the IC50.values for
Ab42(–17–35) and Ab40(–17–35) were dramatically increased
at, 703 lM and 1300 lM, respectively, This ﬁnding suggests
that residues 17–35 indeed have a critical eﬀect on neurotox-
icity. Furthermore, we synthesized truncated Ab peptides lack-
ing residues 17–21, 22–24, and 25–35, and investigated the
neurotoxicity. The related IC50 values for Ab40(–17–21),
Ab42(–17–21), Ab40(–25–35), Ab42(–25–35), Ab40(–22–24),
and Ab42(–22–24) are 327 lM, 208 lM, 272 lM, 150 lM,
128 lM and 110 lM, respectively. Obviously, the IC50 values
for both the 17–21 and 25–35 truncated Ab peptides were sig-
niﬁcantly increased, whereas the IC50 values for the 22–24 trun-
cated Ab peptides were only slightly increased in comparison
with the full-length or the 36–40 truncated Ab peptides. These
results indicate that residues 17–21 and 25–35 may actually play
an important role in the Ab-induced toxicity. Thus, the neuro-
toxicity induced by the Ab peptides is Ab42 > Ab42(–36–40) >
Ab40 > Ab40(–36–40) > Ab42(–22–24) > Ab40(–22–24) >
Ab42(–25–35) > Ab42(–17–21) > Ab40(–25–35) > Ab17–35 >
Ab40(–17–21) > Ab42(–17–35) > Ab40(–17–35) > Ab1–16.
3.2. Aggregative ability of Ab peptides
Neurotoxicity and Ab aggregation have been proposed to be
highly correlated, therefore, the synthesized Ab peptides used
in the neurotoxicity study were used for the aggregation assay.
Fig. 2 shows the result of the aggregation assay for Ab40, Ab42,
Ab42(–36–40), Ab40(–17–35), Ab42(–17–35), Ab42(–17–35),
Ab40(–17–21), Ab40(–22–24), and Ab40(–25–35). It can be
seen that the aggregative ability of Ab42, Ab40 and Ab42
(–36–40) peptides is greater than that of the other truncated
Ab peptides. Comparatively, at around 12 h, the aggregation
of Ab42 reached a steady state, while the aggregation of Ab42
(–36–40) and Ab40 reached a steady state only after18 h. The
Ab40(–25–35) and Ab40(–22–24) peptides reached a steady
state after 18 h and 24 h, respectively, while the Ab40
(–17–21) peptides reached a steady state around 30 h. The ﬂuo-
rescence intensity of residues 25–35, 22–24 and 17–21 truncated
peptides was reduced to half or less compared to the Ab40,
Ab42, and Ab42(–36–40) peptides. Unlike most peptides, the
Ab40(–17–35) and Ab42(–17–35) peptides showed no aggrega-
tion even after 48 h. A similar result was also obtained for Ab1–
16. Basically, the aggregative ability is in the order of Ab42 >
Ab40 @ Ab42(–360–40) > Ab40(–36–40) > Ab42(–22–24) @Ab40(–22–24) > Ab42(–25–35) > Ab40(–25–35) > Ab17–35 >
Ab42(–17–21) > Ab40(–17–21)Ab42(–17–35) @ Ab40(–17–35)
@ Ab1–16.
3.3. Secondary structure analyses
Conversion of the secondary structure into b-sheet confor-
mation is the key step in the formation of Ab aggregates. In
order to examine the relationships between aggregation ability
and secondary structure, CD spectroscopy was used to investi-
gate the propensity of secondary structure for the diﬀerent Ab
peptides. CD spectra for full-length and truncated Ab peptides
are shown in Fig. 3. The calculated secondary structure con-
tent is summarized in Table 2. Result shows that Ab40,Ab42
and Ab17–35 contained the highest ratio of b-sheet (40%,
41% and 45%, respectively), while the Ab1–16 contained 15%
b-sheet, the lowest percentage of b-sheet conformation. Simi-
larly, the Ab40(–17–35) and Ab42(–17–35) peptides also
showed a decrease of b-sheet conformation from 40% to
21  26%. All of these peptides exhibited a dramatic increase
in a-helix conformation. In fact, Ab1–16 showed 57%
a-helix.
The b-sheet content for Ab40(–25–35) and Ab42(–25–35)
was slightly reduced to 35% and 37%, while the Ab40(–17–
21) and Ab42(–17–21) peptides showed a decrease of appro-
ximately 10% in b-sheet content. The secondary structure for
both Ab42(–22–24) and Ab40(–22–24) showed a decline in
the proportion of b-sheet to 21% and 28%, respectively;
however, unlike for the Ab40(–17–35) and Ab42(–17–35)
peptides, no increase of a-helix content was observed. Instead
a signiﬁcant increase of up to 66% and 74% in random coil
content was observed for Ab40(–22–24) and Ab42(–22–24),
respectively. The b-sheet propensity is in the following
order, Ab17–35 > Ab42 @ Ab40 > Ab42(–25–35) @ Ab40(–25–
35) > Ab42(–36–40) @ Ab40(–36–40) > Ab42(–17–21) @ Ab40-
(–17–21) > Ab42(–22–24) @ Ab40(–22–24) > Ab42(–17–35) @
Ab40(–17–35) > Ab1–16. Overall, the relationship between
neurotoxicity and secondary structure is less strongly corre-
lated than that between neurotoxicity and aggregative ability.
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Fig. 3. Far ultraviolet circular dichroism spectra for diﬀerent b-
amyloid peptides: Ab40 (–n–), Ab42 (––), Ab40(–17–21) (–m–),
Ab40(–17–35) (–.–), Ab1–16 (–r–), Ab40 (–36–40) (–b–), Ab40(–25–
35) (–c–), and Ab42(–22–24) ( ). Ab peptides were used at a
concentration of 10 lM for CD measurement.
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The neurotoxicity induced by Ab has been closely linked to
the cascade hypothesis [4,5], which suggests that the Ab adopts
a b-sheet and thereafter aggregates into amyloid-like ﬁbrils.
The aggregated form of Ab has been proposed to induce
neurotoxicity by diﬀerent mechanisms, including free radical
generation [19], oxidative stress [20] or inﬂammation [21].
Although previous work has attempted to elucidate the struc-
tural nature of Ab aggregates, the correlation between neuro-
toxicity and structural properties has not been fully
understood. Therefore, in the present study, we synthesized
diﬀerent truncated Ab peptides and explored the correlation
between structural nature of Ab and the resultant neurotox-
icity.
Based on the present study, residues 17–35 obviously play a
pivotal role in neurotoxicity, aggregative ability and secondary
structure. The IC50 values of the 17–35 truncated peptides dra-
matically increased over 700 lM; the aggregative ability of the
17–35 truncated Ab peptides was completely abolished; and
the content of the b-sheet conformation was reduced with a
signiﬁcant increase of a-helical structure (50%). These results
echo the conclusion obtained from neurotoxicity and aggrega-
tion studies, which suggested that the formation of a-helical
structure inhibits the aggregation of Ab and therefore reduces
its neurotoxicity [22]. On the other hand, residues 36–40 have
little eﬀect on neurotoxicity, aggregative ability, or secondary
structure, since all of the 36–40 truncated peptides showed a
similar level of toxicity and aggregative ability as the full-
length Ab peptides.
With residues 41 and 42, Ab42 has been known to be much
toxic than Ab40 as well as having a greater aggregative ability
both in vivo and in vitro [23]. In the present study, our results
further demonstrated that, except for residues 22–24 truncated
Ab peptides, all Ab peptides with residues I41 and V42 showed
greater toxicity and aggregative ability than those lacking these
two residues. The IC50 values 11 were 1.5–2-fold greater than
those without I41 and V42. This shows that residues 41 and 42
really make a critical contribution to neurotoxicity. The toxi-city induced by residues 22–24 truncated Ab peptides with
and without these two residues did not show a signiﬁcant dif-
ference. Further analyses using either residues 22–24 and 41
(Ab42(–22–24; –41)) or 22–24 and 42 (Ab42(–22–24; –42))
truncated peptides revealed that the IC50 values for Ab42
(–22–24; –41) and Ab42(–22–24; –42) are 116 lM and
118 lM, respectively. This result suggests that there exists a
relationship between residues 41–42 and 22–24. However,
more detailed correlation may need further investigation.
In addition to the eﬀects of residues 17–35 truncated pep-
tides, further analyses of the diﬀerent 17–35 truncated Ab pep-
tides indicate that residues 17–21 and to a less extent 25–35 are
more important for neurotoxicity and aggregative ability than
residues 22–24. Both the 17–21 and 25–35 truncated peptides
showed a signiﬁcant reduction of neurotoxicity and aggrega-
tive ability, while the neurotoxicity and aggregative ability of
the 22–24 truncated peptides did not dramatically decrease in
comparison with full-length or 36–40 truncated Ab peptides.
This result is similar to the previous results by Liu et al. [12],
which indicated that residues 17–20 and 30–35 were the impor-
tant regions for promoting Ab aggregation. The formation of
b-sheet conformation has been proposed to be the key step for
Ab aggregation [22,24], however, the propensity to form b-
sheets by the truncated Ab peptides did not fully correspond
to the neurotoxicity and aggregative ability hierarchy, as the
25–35 truncated peptides adopted a greater proportion of b-
sheets than the other truncated peptides, including the 36–40
truncated Ab peptides. Besides, the IC50 value of Ab17–35,
which lacks the N-terminal residues 1–16, is 300 lM that is
higher than those of the 17–21, 22–24 and 25–35 truncated
Ab peptides. This result is consistent with the previous study
that the P3 peptide, the N-terminal 1–16 truncated 12 peptides,
produced little neurotoxicity [25].
In conclusion, although the formation of the b-sheet confor-
mation is thought to be the key step for Ab aggregation and
neurotoxicity, the present results demonstrated that neurotox-
icity is more strongly correlated with aggregative ability than
secondary structure. Residues 17–21, 25–35 and 41–42 are
the main regions responsible for neurotoxicity and aggrega-
tion.Acknowledgement: This work was supported by grants from National
Science Council of Taiwan, ROC (NSC 952113M320-001 to Y.C.C.)
and Tzu Chi University (TCMR93007 to Y.C.C.).References
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